Open AccessIntravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient’s Activity Level
Author(s) -
Katrin Kofler,
Anke Strölin,
Vanessa Geiger,
Lukas Kofler
Publication year - 2021
Publication title -
journal of cutaneous medicine and surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.593
H-Index - 47
eISSN - 1615-7109
pISSN - 1203-4754
DOI - 10.1177/12034754211003525
Subject(s) - medicine , tolerability , surgery , intravenous immunoglobulin therapy , retrospective cohort study , rivaroxaban , antibody , adverse effect , warfarin , immunology , atrial fibrillation
Livedoid vasculopathy (LV) is a rare disease characterized by livedo racemosa, atrophie blanche, ulcerations, and severe pain. Low molecular weight heparins and rivaroxaban can be used in LV-patients. In addition, intravenous immunoglobulins (IVIG) have been described as treatment-option.